Frexalimab
Frexalimab is an second-generation monoclonal antibody for the treatment of relapsing multiple sclerosis, under developement by Sanofi.

Mechanism of action
It is a CD40 ligand inhibitor.

See also 

 Antibody
 Monoclonal antibody
 Immunology

References 

Breakthrough therapy
Monoclonal antibodies